• About us
• Contact

Advertisement

Organisation › Details

STRÜNGMANN Group (family Strüngmann)

	Region	Germany
	City	n. a.
		Address record changed: 2011-05-15
Basic data	Employees	n. a.
		Record changed: 2025-03-16

Advertisement

More documents for STRÜNGMANN Group (family Strüngmann)

• [1] Aignostics GmbH. (10/29/24). "Press Release: Aignostics Secures $34M Series B to Enhance Precision Medicine with AI". Berlin & New York, NY....
• [2] AiCuris Anti-infective Cures AG. (8/23/23). "Press Release: AiCuris Received 30 Million Euros Milestone Payment from Licensing Partner MSD Following U.S. FDA Approval of Prevymis (letermovir) in Second Indication". Wuppertal....
• [3] AiCuris Anti-infective Cures AG. (7/6/23). "Press Release: AiCuris Announces Strategic Shift to Focus Development and Commercialization of Anti-infectives for Immunocompromised Patients". Wuppertal....
• [4] AMSilk GmbH. (4/4/23). "Press Release: AMSilk Announces Extension of Series C Financing to EUR 54M". Munich....
• [5] AiCuris Anti-infective Cures AG. (4/4/23). "Press Release: AiCuris AG Announces Appointment of Larry Edwards as Chief Executive Officer and Formation of U.S. Subsidiary". Cambridge....
• [6] AiCuris Anti-infective Cures AG. (9/1/22). "Press Release: AiCuris Appoints Experienced Business Leader Dr. Sabrina Kuttruff-Coqui as Chief Financial Officer". Wuppertal....
• [7] AiCuris Anti-infective Cures AG. (2/9/22). "Press Release: AiCuris and Hybridize Therapeutics Enter Worldwide License Agreement of up to €100M for a Direct-acting RNA-based Therapy against BK Virus". Wuppertal & Leiden....
• [8] AiCuris Anti-infective Cures AG. (7/8/21). "Press Release: AiCuris Starts Its First Pivotal Clinical Phase 3 Trial with Pritelivir for the Treatment of Herpes Simplex Virus Infections in Immunocompromised Subjects". Wuppertal....
• [9] AiCuris Anti-infective Cures AG. (5/25/21). "Press Release: AiCuris AG Announces Dr. Stefan Oschmann, Former Merck CEO, to Chair the AiCuris Supervisory Board". Wuppertal....
• [10] AiCuris Anti-infective Cures GmbH. (6/9/20). "Press Release: Royalty Pharma Acquires Partial Royalty Interest on Prevymis (Letermovir) from AiCuris Anti-infective Cures GmbH". New York, NY & Wuppertal....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2025. Made in Germany.